The 2026 trial protocol tests oral probiotics plus a topical stem-cell secretome as add-ons to standard care for mild-to-moderate facial acne. For people with acne-prone skin, the research offers a monitored idea to watch, not a product to buy now. Here oral probiotic means live microbes taken by mouth to help balance gut and skin microbes. Secretome means the mixture of signals and proteins released by mesenchymal stem cells, made into a skin preparation to calm immunity and aid repair.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How is the combination being tested?
- Who fits the mild-to-moderate definition?
- What will researchers measure?
- What should you do with this information?
How is the combination being tested?
According to the PubMed record, every participant stays on standard acne therapy and adds one study combination. The four groups are probiotic with placebo secretome, secretome with placebo probiotic, both actives, or double placebo four-arm design summary.
According to BMJ Open, the plan randomises 64 patients with mild-to-moderate facial acne for 8 weeks, with checks at baseline and after therapy protocol in BMJ Open. The study materials are HEXBIO oral probiotic from B-Crobes Laboratory and secretome from PT Prodia Stem Cell, with bases developed with PT Lunaray Cosmetic.
Who fits the mild-to-moderate definition?
The ICH GCP registry defines mild acne as fewer than 20 comedones or fewer than 15 red bumps or pus spots. It defines moderate acne as 20 to 100 comedones and 20 to 50 such inflammatory lesions, with repeat breakouts in the prior 6 months. Use this quick check before assuming the results would apply to you.
All three points must fit. Severe acne falls outside this protocol. So does mainly chest or back acne, or skin that has stayed clear for months.
- facial acne only, graded mild to moderate
- comedo and bump counts inside those bands
- recent recurrence over 6 months
What will researchers measure?
According to BMJ Open, prespecified outcomes include acne severity grades, faecal and skin microbiome restoration, skin condition, and inflammation markers including interleukin-6 testing. The design therefore looks beyond lesion counts to gut-skin balance and immune response.
The Universitas Padjadjaran summary links the rationale to antibiotic resistance and gut-skin-axis imbalance. In this model, oral probiotics aim to restore microbial balance while the stem-cell secretome aims to steady immune activity and support tissue repair.
What should you do with this information?
A Veeva Clinical Trials listing notes this is a protocol paper with no efficacy results yet. Its 64-person, 8-week design cannot show long-term benefit, safety, or superiority over standard therapy alone.
For now, keep dermatologist-directed care as the base. Do not swap prescriptions for store probiotics or exosome cosmetics. Ask your clinician about proven adjuncts, follow-up timing, and what future results would matter for your breakout pattern.
You Might Also Like
- Skin Microbiome Outcomes in the 2026 Probiotic Acne Review: What the Research Means for People With Acne-Prone Skin
- Recovery and Pigment Safety in the 2026 Split-Face Acne Scar Trial: What the Trial Means for People With Atrophic Acne Scars
- Microbiome-Friendly Acne Care Questions Raised in 2026: Questions People With Acne-Prone Skin Can Ask a Dermatologist